Chief Medical Officer Directorate Pharmacy and Medicines Division



6 August 2021

## **Medicine Supply Alert Notice**

Kolanticon gel<sup>®</sup> (2.5mg dicycloverine hydrochloride, 200mg aluminium hydroxide, 100mg light magnesium oxide, 20mg simethicone per 5ml)

Priority: Level 2\*

Valid until: January 2022

### Issue

- 1. Kolanticon gel<sup>®</sup> is out of stock until January 2022.
- 2. Alternative preparations for symptomatic relief of gastro-intestinal disorders characterised by hyperacidity, smooth muscle spasm, including irritable bowel syndrome (IBS), and flatulence, remain available.

#### **Advice and Actions**

- 3. Where patients have insufficient supplies to last until the re-supply date, clinicians should consider the following:
  - review if treatment is still required;
  - consider switching patients to alternative preparations (see additional information below);and
  - counsel patients on the different product and dosing regimen prescribed.

## **Additional Information**

#### Clinical Information

- 4. Kolanticon gel<sup>®</sup> is licensed for the treatment and prophylaxis of symptoms of peptic ulcer and functional dyspepsia especially in patients in whom gastric distress results from hyperacidity, smooth muscle spasm, including IBS, and flatulence, as well as symptomatic relief in oesophagitis, hiatus hernia, gastritis and iatrogenic gastritis.
- 5. The components of Kolanticon consist of an antacid (magnesium and aluminium), antispasmodic (dicloverine) and antiflatulence agent (simethicone). Although there is no direct equivalent product to Kolanticon Gel® on the UK market, there are alternatives to the components of Kolanticon and choice will depend on symptom(s) being treated. More than one product may be needed if treating more than one symptom. Refer to BNF chapters on antispasmodics, antacids and IBS and NICE CKS guidance on IBS for further information.
- 6. Please refer to SPC for further information:
  - Kolanticon<sup>®</sup>

<sup>\*</sup>https://nhsnss.org/media/3874/medicine-supply-alert-notices-definitions-of-classifications-21-october-2019.docx

# **Enquiries**

7. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to <a href="mailto:PharmacyTeam@gov.scot">PharmacyTeam@gov.scot</a> (primary care) or <a href="mailto:NSS.NHSSMedicineShortages@nhs.scot">NSS.NHSSMedicineShortages@nhs.scot</a> (secondary care).